Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are investigating whether a modified version of metaxalone 640 mg can reduce pain in adults experiencing acute low back and leg pain associated with lumbar spinal stenosis and sciatica. This phase 4, double-blind, randomized, placebo-controlled trial compares the effects of metaxalone plus standard care to a placebo in patients aged 18 to 80 years who are otherwise healthy and have newly occurring pain. Participants will be randomly assigned to one of two groups one receiving metaxalone 640 mg oral tablets every 6 hours for 7 days, and the other receiving an inactive placebo capsule on the same schedule. The study is conducted across multiple centers with a parallel design and includes a pilot phase followed by a larger randomized study. During the trial, participants will complete surveys on Day 1 before treatment and again on Day 7 to report on pain intensity, the impact of pain on physical activity, and sleep interference. The primary outcome measure is the change in the Numeric Pain Scale score from Day 1 to Day 7. Participants will be monitored for adherence and safety throughout the 7-day treatment period.
Actively Recruiting
Researchers are investigating treatment options for people with active rheumatoid arthritis RA who have not responded well to a tumor necrosis factor inhibitor TNFi biologic medication. The study compares two treatment strategies switching to a non-TNFi biologic drug such as rituximab, abatacept, tocilizumab, or sarilumab versus switching to a targeted synthetic disease-modifying antirheumatic drug tsDMARD like tofacitinib, baricitinib, or upadacitinib. This research addresses a significant gap in knowledge as current guidelines recommend switching treatments but lack strong evidence comparing these options directly, especially regarding patient-reported outcomes PROs like function and quality of life. Participants will be randomly assigned to receive either a non-TNFi biologic or a targeted synthetic DMARD. The choice of specific medication within each class is based on what is available and accessible through insurance or patient assistance programs. The study follows a pragmatic design to reflect real-world treatment decisions and includes patients with comorbidities. Treatment continues with stable doses of certain conventional synthetic DMARDs if already being used. This head-to-head trial aims to provide comparative effectiveness data for these two treatment strategies over a 12-month period. During the trial, participants will be monitored for changes in functional limitations using the Health Assessment Questionnaire HAQ, a sensitive tool for measuring outcomes important to patients with RA. Researchers will also track treatment toxicity and quality of life changes. The study involves regular assessments over one year to evaluate the benefits and risks of each treatment approach, helping patients and providers make informed decisions based on outcomes that matter most to patients.